Dear Editor,

Recent failures to improve the prognostic of sepsis have underlined the need for a better phenotypical description of septic subjects. In this view, endocan, an endothelial proteoglycan secreted under proinflammatory conditions, has been described as a useful biomarker to early identify patients at higher risk of poor outcomes during the time course of sepsis \[[@CR1]\]. More recently, a major catabolite of endocan, p14, has been observed at high plasmatic levels in a series of septic subjects, paving the way for a more accurate prediction of poor outcomes in such patients. However, major variations of p14 were observed between patients in this series, with unknown clinical significance \[[@CR2]\]. Furthermore, it is currently unknown whether p14 could undergo renal elimination.

We performed a post hoc analysis based on the data from a previously published prospective cohort of severe septic patients \[[@CR3]\]. Ninety-nine patients underwent measurement of p14 on EDTA plasma. Plasmatic endocan cleavage ratio (ECR) was calculated as plasma p14/(endocan + p14) ratio (endocan and p14 being expressed in pmol/mL) on baseline and 24 h, 48 h, and 72 h following ICU admission. Baseline characteristics of patients are exposed in Additional file [1](#MOESM1){ref-type="media"}.

In this cohort, ECR on enrolment was correlated with baseline SAPS 2 (*ρ* = 0.36, 95% CI (0.17--0.53); *p* \<  10^− 3^) and SOFA (*ρ* = 0.21 (0--0.39); *p* = 0.04). Renal SOFA was the only component of SOFA score associated with higher ECR, with median \[IQR\] baseline ECR observed at 0.38 \[0.29--0.61\] in patients with baseline renal SOFA \> 2 vs 0.28 \[0.19--0.36\] in patients with baseline renal SOFA ≤ 2 (*p* \<  10^− 3^) (Table [1](#Tab1){ref-type="table"}). Over 72 h, patients with a baseline renal SOFA at 4 had higher median plasmatic ECR than those with baseline renal SOFA \< 4 (*p* \<  10^− 3^) (Fig. [1](#Fig1){ref-type="fig"}).Table 1Endocan cleavage ratio (ECR) according to patients' characteristicsVariablesAbsentPresentSpearman *ρ* (95% CI)*p*Age (years)0.18 (− 0.03--0.37)0.08Chronic comorbidities COPD0.33 \[0.21--0.42\]0.23 \[0.18--0.51\]0.53 Smoker0.33 \[0.21--0.45\]0.23 \[0.18--0.35\]0.15 Cardiomyopathy0.3 \[0.2--0.42\]0.33 \[0.2--0.45\]0.61 Chronic kidney failure0.31 \[0.21--0.44\]0.25 \[0.05--0.56\]0.7 Cirrhosis0.31 \[0.2--0.45\]0.3 \[0.21--0.37\]0.63Sepsis severity on enrolment Severe sepsis0.29 \[0.2--0.41\] Septic shock0.31 \[0.2--0.45\]0.74Site of infection on enrolment Soft tissues0.3 \[0.2--0.39\] Respiratory0.33 \[0.21--0.45\] Urinary0.31 \[0.22--0.53\]0.82 Digestive0.31 \[0.24--0.38\] Other0.21 \[0.07--0.49\]Biomarkers on enrolment CRP (mg/L)0 (−0.21--0.2)0.96 PCT (ng/mL)0.06 (− 0.15--0.26)0.58Prognostic scores on enrolment SAPS 20.36 (0.17--0.53)\< 10^−3^ SOFA0.21 (0--0.39)0.04 LIPS0.12 (−0.08--0.32)0.22Organ SOFA \> 2 on enrolment Pulmonary0.3 \[0.2--0.37\]0.35 \[0.24--0.48\]0.19 Renal0.28 \[0.19--0.36\]0.38 \[0.29--0.61\]\< 10^− 3^ Hepatic0.32 \[0.21--0.42\]0.26 \[0.14--0.53\]0.75 Circulatory0.23 \[0--0.39\]0.33 \[0.23--0.45\]0.12 Neurological0.3 \[0.2--0.38\]0.33 \[0.24--0.48\]0.19 Hematological0.31 \[0.2--0.4\]0.27 \[0.12--0.54\]0.99Mortality Day 280.3 \[0.19--0.38\]0.33 \[0.23--0.48\]0.4 ICU discharge0.3 \[0.2--0.37\]0.33 \[0.23--0.54\]0.24ICU length of stay (days)0.16 (−0.04--0.35)0.11Mechanical ventilation on enrolment0.3 \[0.19--0.37\]0.31 \[0.23--0.47\]0.33ECR are presented as median \[IQR\] values according to presence or absence of categorical variables. A Mann-Whitney test was used for comparison between two groups. A Kruskal-Wallis test was used for comparison between three or more groups. Correlations between ECR and continuous variables are described through Spearman *ρ* (95% CI)*COPD* chronic obstructive pulmonary disease, *SOFA* Sequential Organ Failure Assessment, *ICU* intensive care unit, *SAPS 2* Simplified Acute Physiology Score 2, *LIPS* Lung Injury Prediction ScoreFig. 1**a** Box plots of plasmatic endocan cleavage ratio (ECR) on enrolment according to baseline renal SOFA. Box plot shows the median (horizontal line) and IQR (25th--75th percentile) (box). The whiskers show the lowest data within 1.5 IQR of the lower quartile and highest data within 1.5 IQR of the upper quartile; data outside 1.5 IQR of the upper or lower quartiles are depicted with a dot. Comparison between subjects with renal SOFA \> 2 vs renal SOFA ≤ 2 was performed with the Mann-Whitney test. \*: *p* \<  10^− 3^. **b** Kinetics of plasmatic ECR median values over 72 h following enrolment according to baseline renal SOFA

Our results suggest that circulating concentrations of p14 might be influenced by the severity of acute renal failure. Therefore, it could be proposed that, by contrast with endocan, p14 could be eliminated through glomerular filtration, thus suggesting that it should be measured in urine rather that in blood. This discrepancy might be explained by the smaller molecular weight of p14, as well as the absence of polyanionic glycanic chain on its protein core. Further explorations are needed to confirm these hypotheses.
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